Back to Search
Start Over
Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status.
- Source :
-
The Journal of dermatological treatment [J Dermatolog Treat] 2021 Mar; Vol. 32 (2), pp. 203-211. Date of Electronic Publication: 2019 Dec 08. - Publication Year :
- 2021
-
Abstract
- Objectives: To compare treatment patterns and costs among psoriasis patients with and without metabolic conditions newly initiating a biologic or apremilast.<br />Methods: Adult patients included had ≥1 prescription for secukinumab, adalimumab, ustekinumab, etanercept, or apremilast between 01/01/2015 and 08/31/2018 (date of first prescription was index date) and no index drug use in the 12-months pre-index, and continuous enrollment in the 12-month pre-index and 24-month post-index periods. Patients were divided into mutually exclusive treatment cohorts and stratified by their pre-index metabolic condition status. Treatment patterns (adherence, non-persistence, switching, discontinuation, use of combination therapy, and re-initiation) and healthcare costs were compared.<br />Results: Overall, 7773 patients were included; 47.5-56.7% had a metabolic condition. Except for the apremilast group, patients with metabolic conditions had higher discontinuation (secukinumab: 50.6% vs. 43.7%; adalimumab*: 53.9% vs. 48.7%; ustekinumab*: 41.9% vs. 35.1%; etanercept: 42.8% vs. 41.2%; apremilast: 43.1% vs. 46.1%) and switching (secukinumab: 48.1% vs. 41.2%; adalimumab*: 47.8% vs. 41.9%; ustekinumab*: 34.5% vs. 25.3%; etanercept*: 53.6% vs. 51.5%; apremilast: 45.8% vs. 44.6%) than patients without (* p < .05). Patients with metabolic conditions incurred significantly higher costs.<br />Conclusion: Many psoriasis patients initiating biologics or apremilast had metabolic conditions. These patients had higher discontinuation and switching, and significantly higher healthcare costs.
- Subjects :
- Adalimumab economics
Adalimumab therapeutic use
Adult
Databases, Factual
Dermatologic Agents economics
Etanercept economics
Etanercept therapeutic use
Female
Humans
Male
Medication Adherence
Middle Aged
Psoriasis economics
Retrospective Studies
Thalidomide analogs & derivatives
Thalidomide economics
Thalidomide therapeutic use
Treatment Outcome
Ustekinumab economics
Ustekinumab therapeutic use
Dermatologic Agents therapeutic use
Health Care Costs statistics & numerical data
Psoriasis drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1471-1753
- Volume :
- 32
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- The Journal of dermatological treatment
- Publication Type :
- Academic Journal
- Accession number :
- 31769703
- Full Text :
- https://doi.org/10.1080/09546634.2019.1698699